These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 38992954)

  • 1. Simultaneous detection of three hypoxia-inducible factor stabilizers-molidustat, roxadustat, and vadadustat-in multiple keratinized matrices and its application in a doping context.
    Checkouri A; Gheddar L; Arbouche N; Raul JS; Kintz P
    Drug Test Anal; 2024 Jul; ():. PubMed ID: 38992954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First detection/quantification of roxadustat in hair with a new liquid chromatography with tandem mass spectrometry method: Application to a treated patient.
    Alvarez JC; Etting I; Juillard L; Massy Z; Larabi IA
    Clin Chim Acta; 2023 Jun; 546():117395. PubMed ID: 37211176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A network meta-analysis of the efficacy of hypoxia-inducible factor prolyl-hydroxylase inhibitors in dialysis chronic kidney disease.
    Chen J; Shou X; Xu Y; Jin L; Zhu C; Ye X; Mei Z; Chen P
    Aging (Albany NY); 2023 Mar; 15(6):2237-2274. PubMed ID: 36988549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mass spectrometric characterization of the hypoxia-inducible factor (HIF) stabilizer drug candidate BAY 85-3934 (molidustat) and its glucuronidated metabolite BAY-348, and their implementation into routine doping controls.
    Dib J; Mongongu C; Buisson C; Molina A; Schänzer W; Thuss U; Thevis M
    Drug Test Anal; 2017 Jan; 9(1):61-67. PubMed ID: 27346747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First evidence of the incorporation of daprodustat and other hypoxia-inducible factor stabilizers into equine hair by passive transfer based on segmental quantitative analysis.
    Ishii H; Shibuya M; Kusano K; Sone Y; Kamiya T; Wakuno A; Ito H; Miyata K; Yamada M; Leung GN
    J Pharm Biomed Anal; 2023 Oct; 235():115600. PubMed ID: 37516063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. UPLC-MS-Based Procedures to Detect Prolyl-Hydroxylase Inhibitors of HIF in Urine.
    Mazzarino M; Perretti I; Stacchini C; Comunità F; de la Torre X; Botrè F
    J Anal Toxicol; 2021 Feb; 45(2):184-194. PubMed ID: 32435795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Testing for clomiphene in keratinous matrices using LC-MS/MS in doping purpose: Is a single intake of clomiphene detectable in hair and nail clippings?
    Gheddar L; Ameline A; Arbouche N; Blanchot A; Raul JS; Kintz P
    J Pharm Biomed Anal; 2024 Feb; 239():115888. PubMed ID: 38096632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of outcomes on hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) in anaemia associated with chronic kidney disease: network meta-analyses in dialysis and non-dialysis dependent populations.
    Sackeyfio A; Lopes RD; Kovesdy CP; Cases A; Mallett SA; Ballew N; Keeley TJ; Garcia-Horton V; Ayyagari R; Camejo RR; Johansen KL; Sutton AJ; Dasgupta I
    Clin Kidney J; 2024 Jan; 17(1):sfad298. PubMed ID: 38250252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of Hypoxia-Regulated MicroRNAs in Blood as Potential Biomarkers of HIF Stabilizer Molidustat.
    Marchand A; Roulland I; Semence F; Schröder K; Domergue V; Audran M
    Microrna; 2019; 8(3):189-197. PubMed ID: 30657053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Body fluid contamination in the context of an adverse analytical finding in doping: About a case involving ostarine.
    Alvarez JC; Etting I; Larabi IA
    Clin Chim Acta; 2024 Apr; 557():117871. PubMed ID: 38467244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. lmplementation of the prolyl hydroxylase inhibitor Roxadustat (FG-4592) and its main metabolites into routine doping controls.
    Eichner D; Van Wagoner RM; Brenner M; Chou J; Leigh S; Wright LR; Flippin LA; Martinelli M; Krug O; Schänzer W; Thevis M
    Drug Test Anal; 2017 Nov; 9(11-12):1768-1778. PubMed ID: 28378453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The comparison of four hypoxia-inducible factor prolyl hydroxylase inhibitors on drug potency and cost for treatment in patients with renal anemia.
    Imai E; Imai A
    Clin Exp Nephrol; 2024 May; ():. PubMed ID: 38767688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitors in anaemia of chronic kidney disease: A meta-analysis including 13,146 patients.
    Chen H; Cheng Q; Wang J; Zhao X; Zhu S
    J Clin Pharm Ther; 2021 Aug; 46(4):999-1009. PubMed ID: 33615523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Potential of Hypoxia Inducible Factors Prolyl Hydroxylase Inhibitors in Treating Nonanemic Diseases.
    Miao M; Wu M; Li Y; Zhang L; Jin Q; Fan J; Xu X; Gu R; Hao H; Zhang A; Jia Z
    Front Pharmacol; 2022; 13():837249. PubMed ID: 35281917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hair and dietary supplements testing to identify contamination with roxadustat in an adverse analytical finding.
    Alvarez JC; Etting I; Gheddar L; Kintz P; Larabi IA
    J Pharm Biomed Anal; 2024 Feb; 239():115915. PubMed ID: 38091820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of HIF prolyl-hydroxylase inhibitor vs epoetin and darbepoetin for anemia in chronic kidney disease patients not undergoing dialysis: A network meta-analysis.
    Zheng Q; Yang H; Sun L; Wei R; Fu X; Wang Y; Huang Y; Liu YN; Liu WJ
    Pharmacol Res; 2020 Sep; 159():105020. PubMed ID: 32561478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKD.
    Gupta N; Wish JB
    Am J Kidney Dis; 2017 Jun; 69(6):815-826. PubMed ID: 28242135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Prospective Randomized Controlled Clinical Study to Investigate the Efficacy and Safety of Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitors in Non-Dialysis Patients with Chronic Heart Failure and Renal Anemia Switched from Continuous Erythropoietin Receptor Activator Treatment.
    Sezai A; Abe M; Maruyama T; Taoka M; Sekino H; Tanaka M
    J Clin Med; 2024 May; 13(10):. PubMed ID: 38792306
    [No Abstract]   [Full Text] [Related]  

  • 19. Segmental analysis and long-term monitoring of vadadustat in equine hair for the purpose of doping control.
    Ishii H; Shibuya M; Kusano K; Sone Y; Kamiya T; Wakuno A; Ito H; Miyata K; Yamada M; Leung GN
    J Anal Toxicol; 2023 Sep; 47(7):623-631. PubMed ID: 37632695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Automated sample preparation for the detection and confirmation of hypoxia-inducible factor stabilizers in urine.
    De Wilde L; Roels K; Deventer K; Van Eenoo P
    Biomed Chromatogr; 2021 Feb; 35(2):e4970. PubMed ID: 32840903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.